Univ Paris Sud, Physico-chimie, Pharmacotechnie et Biopharmacie, UMR 8612, Châtenay-Malabry F-92296, France.
J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Mar 1;887-888:128-32. doi: 10.1016/j.jchromb.2012.01.025. Epub 2012 Jan 30.
The long-term clinical use of doxorubicin (Dox), one of the most important anticancer agent in use, is limited by dose-related acute cardiotoxicity, myelo-suppression and multidrug resistance developed by cancer cells. To improve the antitumor efficacy and reduce the toxicity of Dox, many drug delivery systems have been developed, including poly(alkylcyanoacrylate) (PACA) nanoparticles. A new formulation of PACA nanoparticles with potential stealth properties were prepared by redox radical emulsion polymerization and associated to Dox in our laboratory. To comparatively investigate the pharmacokinetics and the biodistribution of different formulations of Dox associated PACA nanoparticles, a simple and rapid high performance liquid chromatographic method (HPLC) was developed for the quantification of Dox in plasma and tissues of rats treated with Dox loaded PACA nanoparticle (Dox-PACA). Dox was eluted at 4.4 min and it was well separated from its main metabolites doxorubicinol (Doxl) and doxorubicinon (Doxon) and idarubicin (Ida) used as internal standard (IS). Extraction of Dox from biological media was achieved by liquid-liquid extraction. The recovery of total Dox (i.e. free Dox and Dox associated with nanoparticles) from plasma and tissues (liver, spleen and heart) spiked with Dox-PACA were 71 and 78% for 0.05 and 1 μg/mL in rat plasma, respectively, and 73% and 80% for 0.5 and 10 μg/g in tissues, respectively. The method is linear from 0.05 to 1.5 μg/mL of Dox in plasma. The limit of detection of the method is 0.5 ng of Dox per injection (50 μL). The between-day and within-day precisions of the method were 97.1-102.9% and 97.3-101.7% for concentrations ranging from 0.05 to 1 μg/mL, respectively. Preliminary data suggested that this method can be applied to determine the pharmacokinetic and biodistribution of Dox associated with PACA nanoparticles after intravenous administration to rats.
多柔比星(Dox)是一种最重要的抗癌药物之一,其长期临床应用受到剂量相关的急性心脏毒性、骨髓抑制和癌细胞产生的多药耐药性的限制。为了提高抗肿瘤疗效和降低多柔比星的毒性,已经开发了许多药物递送系统,包括聚(烷基氰基丙烯酸酯)(PACA)纳米粒子。我们实验室通过氧化还原自由基乳液聚合制备了具有潜在隐形特性的新型 PACA 纳米粒子制剂,并将其与多柔比星偶联。为了比较研究不同制剂的多柔比星偶联 PACA 纳米粒子的药代动力学和生物分布,我们开发了一种简单快速的高效液相色谱法(HPLC),用于定量检测大鼠血浆和组织中多柔比星负载 PACA 纳米粒子(Dox-PACA)处理后的多柔比星。多柔比星在 4.4 分钟洗脱,与主要代谢物多柔比星醇(Doxl)、多柔比星酮(Doxon)和伊达比星(Ida)(作为内标(IS))完全分离。通过液-液萃取从生物介质中提取多柔比星。从大鼠血浆和组织(肝、脾和心)中提取多柔比星- PACA 加标物的总多柔比星(即游离多柔比星和与纳米粒子结合的多柔比星)回收率分别为 0.05 和 1μg/mL 时为 71%和 78%,0.5 和 10μg/g 时为 73%和 80%。该方法在大鼠血浆中多柔比星 0.05 至 1.5μg/mL 范围内呈线性。该方法的检测限为 50μL 注射量的 0.5ng 多柔比星。该方法的日间和日内精密度分别为 0.05 至 1μg/mL 浓度范围的 97.1-102.9%和 97.3-101.7%。初步数据表明,该方法可用于测定静脉注射多柔比星与 PACA 纳米粒子偶联物后在大鼠体内的药代动力学和生物分布。